Tetra Bio-Pharma Plays to Its Strengths with Pharma Approach, Plus Exclusive Interview

Ryan Allway

May 4th, 2017

News, Top News

The cannabis industry is expected to rapidly expand over the coming years, which has created many opportunities for investors in the space. With competition intensifying, investors should seek out companies taking a novel approach with high barriers to entry. Pharmaceutical-focused companies may be the best opportunities since clinical trials represent a high barrier to entry and the products are in-demand from patients suffering from a wide array of conditions.

In this article, we will take a closer look at Tetra Bio-Pharma Inc. (CSE: TBP) (OTC: GRPOF) and its transition to a pharmaceutical-like approach to the cannabis industry.

Taking a Refined Approach

The U.S. cannabis industry is expected to surpass $50 billion by 2026, according to Cowen & Co., while Deloitte sees Canada’s industry reaching C$22.6 billion over the coming years. While there are no shortage of opportunities for investors, these strong growth rates have created intensifying competition across all areas of the market. This means that investors should focus their attention on companies that have built unique and valuable businesses.

Tetra Bio-Pharma has shifted its focus from a medical marijuana company to a cannabinoid-centric pharmaceutical company. By partnering with industry leaders, the company can focus on putting patients first and leverage its own strengths to bring high-quality products to market. The result is an investment opportunity with less execution risk, reduced capital expenditures, and a greater probability of building long-term shareholder value.

Recently, CFN Media sat down with Dr. Guy Chamberland, CSO, to discuss the company’s new approach and the status of its clinical programs and partnerships:

Smoked Cannabis Trials

Most mainstream physicians are hesitant to recommend the use of medical marijuana to treat any medical conditions due to the lack of controlled clinical trials. In many cases, there’s only anecdotal evidence of efficacy in treating certain medical conditions and several studies have shown possible negative side-effects. There’s also a huge difference between various strains available on their market and very little data supporting one over another.

Tetra Bio-Pharma’s flagship clinical program intends to assess the safety and efficacy of smoked marijuana in treating pain in patients with cancer and AIDS. By doing so, the company aims to achieve prescription drug coverage to make medical marijuana more affordable for patients while reassuring physicians that the treatment is both safe and efficacious. The move could have tremendous implications for the industry that still struggles with a negative stereotype.

The team worked closely with U.S. and Canadian regulators to design and implement a Phase I safety trial (ongoing) that will eventually move to a large-scale Phase III efficacy trial targeting pain in patients where opioids and other options have been ineffective. Investors should keep an eye on the stock as these clinical trials progress, since milestone markers could become significant catalysts for the stock price over the coming quarters.

Partnerships & Personnel

Tetra Bio-Pharma has recently unveiled several different partnerships that help expand its footprint and advance its clinical pipeline. In addition to these partnerships, the company recently announced a new employment agreement with Denis Courchesne, who will serve as Vice President of Sales. Mr. Courchesne has over 25 years of experience in retail sales working for companies like Pfizer Inc. (NYSE: PFE) and Evian Spring Water.

On April 3, the company announced a definitive agreement to develop and commercialize a drug product containing dronabinol for the management of anorexia and cancer chemotherapy-related pain. The new product will be an oral mucoadhesive tablet based on IntelGenx’s proprietary AdVersa® technology, which avoids common side-effects associated with the original drug, including upset stomach and headache.

On April 19, the company announced plans for the joint distribution of dried medical cannabis in the maritime provinces and Quebec with Aphria Inc. (TSX-V: APH) (OTC: APHQF). The agreement provides the company with dried cannabis for use in its aforementioned clinical trial program while generating near-term revenue to help finance the program’s development. This is a win-win for shareholders and helps the company avoid the cost of establishing its own grow operations.

Looking Ahead

Tetra Bio-Pharma Inc. (CSE: TBP) (OTC: GRPOF) represents a compelling investment opportunity in the burgeoning cannabis industry. By taking a pharmaceutical-like approach to the market, the company is uniquely positioned to advance its clinical programs and unlock significant benefits for patients and value for shareholders. Investors may want to keep an eye on the stock given these dynamics and near-term catalysts.

For more information, visit the company’s website or CannabisFN’s company profile.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Search CannabisFN

Press Coverage

Psychedelics Index

Visit the CFN Video Library

Join Our Facebook Page

Top Videos

Sumit Mehta of MAZAKALI

In addition to his role as Founder and CEO at MAZAKALI, Sumit is a consultant to The Arcview Group and the Managing Partner of Emerald Ventures. A frequent speaker at investment seminars, Sumit acts as a mentor to Arcview and Canopy companies and serves on the Canopy Investment committee as well as the NCIA Finance […]

Neill Dixon of O’Cannabiz Conference & Expo

The producers of O’ Cannabiz have decades of experience producing national-profile events and creating global connections between business communities in the arts, broadcasting, media and technology. They have organized trade summit initiatives with governments around the world. And they have worked closely with sponsors in all levels of Canadian government.

Cansortium

Cansortium is a US Based, vertically integrated cannabis company with a global mission: deliver the highest standards of cannabis care from nursery to lab to shelf.

Chemesis International Inc.

Chemesis International is a vertically integrated global leader in the cannabis industry, currently operating within Puerto Rico, and California.

Network Partners

Follow Us on Social Media

Facebook

Twitter

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.